Global Blood Plasma Derivatives Market Strategies 2024, Forecast To 2033
8 Mar, 2024
The blood plasma derivatives market size has grown strongly in recent years, from $48.26 billion in 2023 to $52.61 billion in 2024 at a compound annual growth rate (CAGR) of 9.0%. The growth in the historic period can be attributed to increased prevalence of hemophilia and bleeding disorders, growth in the geriatric population, increased awareness and diagnosis, rise in surgical procedures, and global blood transfusion services. The market is expected to see strong growth in the next few years, reaching $75 billion in 2028 at a CAGR of 9.3%. This growth can be attributed to the emergence of rare disease therapies, growth in chronic diseases, increasing healthcare expenditure, patient-centric treatment approaches, and growing healthcare infrastructure. Major trends in the forecast period include advancements in fractionation technologies, patient-centric approaches, collaborations and partnerships, expanding applications in neurology, and technological innovations in plasma fractionation.
Global Blood Plasma Derivatives Market Key Driver
The increasing prevalence of immunodeficiency disorders is expected to drive the growth of the blood plasma derivatives market. Immunodeficiency disorders compromise the immune system, and blood plasma derivatives, including immunoglobulins, are used in treating these disorders. Malnutrition contributes to immunodeficiency, with global hunger impacting 828 million people in 2021, as reported by the World Health Organization (WHO). Therefore, the rising prevalence of immunodeficiency disorders, fueled by factors like malnutrition, is driving the growth of the blood plasma derivatives market.
Get A Free Sample Of The Global Blood Plasma Derivatives Market ReportGlobal Blood Plasma Derivatives Market Segments
The blood plasma derivatives market covered in this report is segmented –
1) Type:Albumin, Factor VIII, Factor IX, Immunoglobulin, Hyperimmune Globulin, Other Types
2) Application:Hemophilia, Hypogammaglobulinemia, Immunodeficiency Diseases, Von Willebrand's Disease, Other Applications
3) End-User:Hospitals, Clinics, Other End-Users
By Geography: The countries covered in the blood plasma derivatives market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
North America was the largest region in the blood plasma derivatives market in 2023. The regions covered in the blood plasma derivatives market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Major Blood Plasma Derivatives Industry Players
Bayer AG; Sanofi S.A.; Takeda Pharmaceutical Company Limited; Baxter International Inc.; CSL Limited; Meiji Group; Grifols S.A.; Shire Pharmaceuticals Inc.; GC Biopharma Corp; Emergent BioSolutions Inc.; Shanghai Raas Blood Products Co Ltd.; Kedrion S.p.A.; Sanquin; Biotest AG; Bio Products Ltd.; ADMA Biologics Inc.; China Biologic Products Holdings Inc.; BioIVT; PlasmaGen BioSciences Pvt. Ltd.; Virchow Biotech Private Limited; LFB S.A.; Monobind Inc.; Intas Pharmaceuticals Ltd.; Octapharma Plasma; Fusion Pharmaceuticals Inc.
Get The Full Global Blood Plasma Derivatives Market ReportBlood Plasma Derivatives Market Overview
Blood plasma derivatives are medicinal products crafted from refined proteins found in blood plasma, encompassing clotting factors, albumins, and other proteins employed to treat diverse medical ailments. These derivatives hold significant significance as they aid in replenishing absent or inadequate proteins within the body.